2024
Novartis Boosts 2024 Sales Forecast, Gears Up for Major Cancer Drug Expansions
Novartis, 2024 sales outlook, cancer drugs, drug expansions, pharmaceutical industry, healthcare, oncology.
Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment
Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.
Roche’s Strategic Shift Affects 20% of New Molecules, as Cancer Candidates are Reassessed
Roche, pipeline, rethink, new molecules, cancer candidates, discard pile, strategic shift, pharmaceutical industry, drug development, oncology research
From Alpine’s Elite Data Room to Vertex’s VIP: A Shift in Biotech Dominance
Alpine, Vertex, biotech, data room, exclusivity, VIP, shift, dominance.
Xaira: The Billion-Dollar AI-Powered Drug Discovery Startup Revolutionizing Healthcare
Xaira, AI, drug discovery, healthcare, startup, funding, billion-dollar, revolutionizing, pharmaceuticals, biotechnology.
Roche Streamlines Portfolio, Prioritizes High-Impact Projects After Pipeline Reduction
Roche, pharmaceuticals, pipeline, portfolio optimization, high-impact projects, strategic decision, drug development
Neurocrine Biosciences and Takeda’s Collaborative Drug Shows Promising Results in Phase II Clinical Trial for Depression
Neurocrine Biosciences, Takeda, drug candidate, Phase II clinical trial, depression, promising results.
BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry
BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.
Revolutionizing Research and Development: Xaira Unveils AI-Driven Platform with $1B Funding and Former Genentech Leaders
AI-Powered Xaira, $1B funding, Genentech executives, R&D transformation, biotechnology innovation, artificial intelligence in research, life sciences advancement.
BenevolentAI Downsizes Operations, Cuts 30% of Workforce Amidst Funding Challenges
BenevolentAI, layoffs, workforce reduction, funding gap, US site closure, AI research, drug discovery